Data di Pubblicazione:
2006
Citazione:
Neutralising antibodies to IFN-β in patients with multiple sclerosis / F. Bagnato, M. Riva, G. Antonelli. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - 6:8(2006), pp. 773-785. [10.1517/14712598.6.8.773]
Abstract:
The development of neutralising antibodies (NABs), or neutralising activity in the absence of NABs, is a potential complication of therapy with interferon (IFN)-β for patients with multiple sclerosis, limiting therapeutic efficacy. Discontinuation of IFN-β therapy in patients found to have sustained titres of NABs > 1:100 over an interval of 3 - 6 months has been recently proposed as a Level A recommendation. The extent to which NABs are causative, rather than an epiphenomenon, in determining drug failure has been a matter of numerous investigations and is still controversial. Thus, further studies are warranted for determining the role that NABs may play in reducing the response to the drug. In particular, the effects of NABs in reducing the efficacy of IFN-β therapy beyond clinical relapse rate and lesion load on conventional imaging are not as yet fully understood. © 2006 Informa UK Ltd.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Interferon-β; Multiple sclerosis; Neutralising antibodies; Adjuvants, Immunologic; Antibodies; Clinical Trials as Topic; Humans; Interferon-beta; Interferons; Multiple Sclerosis; Recurrence; Time Factors; Treatment Outcome; Pharmacology; Drug Discovery3003 Pharmaceutical Science; Clinical Biochemistry
Elenco autori:
F. Bagnato, M. Riva, G. Antonelli
Link alla scheda completa: